Blueprint Medicines Corporation

Quick facts

Phase 2 pipeline

• BLU-808 · Oncology
  BLU-808 is a potent and selective KIT inhibitor.

Phase 1 pipeline

• BLU-782
• BLU-782 taken with food

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Blueprint Medicines Corporation portfolio CI brief
• Blueprint Medicines Corporation pipeline updates RSS